Vertex Q3 revenue $3.44B, guidance set; Crinetics deal disclosed

Vertex’s Q3 2026 revenue hit $3.44 billion, up 12% year-over-year, with guidance of $13.15–$13.25 billion and a Crinetics deal at $10 billion equity plus $9 billion net cash. The source supports these figures but does not confirm a causal link from cystic fibrosis revenue to expansion in other…

Share
Vertex Pharmaceuticals Q3 2026 revenue of $3.44 billion, year-over-year growth, and Crinetics acquisition terms shown on a financial summary slide.